Bruker Corporation
BRKR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.04 | 0.55 | 3.69 | 0.59 |
| FCF Yield | 1.56% | 2.26% | 1.41% | 1.50% |
| EV / EBITDA | 24.62 | 19.45 | 19.68 | 26.09 |
| Quality | ||||
| ROIC | 3.06% | 10.73% | 11.35% | 10.37% |
| Gross Margin | 49.00% | 51.05% | 51.59% | 50.03% |
| Cash Conversion Ratio | 2.21 | 0.82 | 0.92 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.98% | 7.03% | 8.39% | 5.27% |
| Free Cash Flow Growth | -44.08% | 70.07% | -24.89% | -18.98% |
| Safety | ||||
| Net Debt / EBITDA | 4.70 | 1.49 | 1.05 | 0.54 |
| Interest Coverage | 5.28 | 26.64 | 26.88 | 28.90 |
| Efficiency | ||||
| Inventory Turnover | 1.61 | 1.50 | 1.52 | 1.70 |
| Cash Conversion Cycle | 238.55 | 269.12 | 272.17 | 232.91 |